Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.58 |
| ▸ | MAPT | P10636 | 5/20 | 0.58 |
| ▸ | HTT | P42858 | 3/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.57 |
| ▸ | LMNA | P02545 | 4/20 | 0.57 |
| ▸ | XBP1 | P17861 | 2/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | GOT1 | P17174 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | RAF1 | P04049 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27993813 | 0.87 | RXFP1 (0.55) | MEN1KMT2AMAPTHTTRAB9A | |
| SCHEMBL12989341 | 0.84 | LMNA (0.71) | MEN1KMT2AMAPTHTTRAB9A | |
| SCHEMBL965139 | 0.83 | SMN1; SMN2 (0.64) | MEN1KMT2AMAPTHTTRAB9A | |
| SCHEMBL14685427 | 0.82 | MAPT (0.66) | MEN1KMT2AMAPTHTTRAB9A | |
| SCHEMBL5759619 | 0.82 | MEN1 (0.61) | MEN1KMT2AMAPTHTTRAB9A | |
| SCHEMBL30797249 | 0.81 | MAPT (0.64) | MEN1KMT2AMAPTHTTRAB9A | |
| SCHEMBL13737287 | 0.81 | MAPT (0.64) | MEN1KMT2AMAPTHTTRAB9A | |
| SCHEMBL3429585 | 0.81 | MAPT (0.68) | MEN1KMT2AMAPTHTTRAB9A | |
| SCHEMBL15841187 | 0.81 | MAPT (0.50) | MEN1KMT2AMAPTHTTRAB9A | |
| SCHEMBL27768800 | 0.80 | SMN1; SMN2 (0.75) | MEN1KMT2AMAPTHTTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9040516-B2 | Uracil derivative and use thereof for medical purposes | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2015-05-26 | — | — | US | disclosed |
| US-20140179670-A1 | URACIL DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2014-06-26 | — | — | US | disclosed |
| EP-2740728-A1 | URACIL DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2014-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179670-A1 | URACIL DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | URB2, ELANE, NUDT1 | MEN1 4078/4885KMT2A 4525/4885MAPT 4663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.